|Articles|March 18, 2022
Supplying CleanCap® Reagent for a COVID-19 Vaccine
Author(s)TriLink BioTechnologies
This case study demonstrates scale-up of mRNA supply chain, increased quality standards, and global supply capabilities within record-breaking time.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma
2
The FDA Moves to Modernize Drug Manufacturing Registration
3
PharmTech Weekly Roundup–July 10, 2026
4
What the Ocrelizumab Deal Does for the Multiple Sclerosis Biosimilar Pipeline
5